Gujarat Themis Biosyn Ltd
GUJTHEMGujarat Themis Biosyn Ltd
GUJTHEM
Price Chart
Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 67.42 | 17.64 | 1.02% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
The company makes bulk drugs. It's R&D division focuses on developing fermentation cultures. The Company's products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 32.79 | 36.05 | 38.97 | 43.26 | 86.82 | 93.83 | 118.90 | 154.98 | 174.20 | 157.26 | ||||||||||
Raw Materials | 0.32 | 1.49 | 2.15 | 1.30 | 15.44 | 15.75 | 21.75 | 29.73 | 25.67 | 81.78 | ||||||||||
| Power & Fuel Cost | 17.15 | 17.99 | 19.33 | 20.20 | 22.86 | 16.57 | 21.73 | 26.41 | 26.53 | |||||||||||
| Employee Cost | 4.28 | 4.42 | 4.46 | 5.17 | 6.43 | 7.11 | 7.08 | 7.75 | 10.21 | |||||||||||
| Selling & Administrative Expenses | 0.94 | 0.85 | 1.10 | 1.39 | 1.64 | 1.86 | 2.31 | 6.66 | 8.51 | |||||||||||
| Operating & Other expenses | 3.90 | 4.90 | 5.52 | 5.62 | 6.91 | 8.94 | 3.94 | 4.20 | 20.18 | |||||||||||
EBITDA | 6.20 | 6.40 | 6.41 | 9.58 | 33.54 | 43.60 | 62.09 | 80.23 | 83.10 | 75.48 | ||||||||||
| Depreciation/Amortization | 1.20 | 1.12 | 1.15 | 1.22 | 1.36 | 1.73 | 2.23 | 2.58 | 3.54 | 4.49 | ||||||||||
| PBIT | 5.00 | 5.28 | 5.26 | 8.36 | 32.18 | 41.87 | 59.86 | 77.65 | 79.56 | 70.99 | ||||||||||
| Interest & Other Items | 0.38 | 0.41 | 0.42 | 0.16 | 0.92 | 0.98 | 0.83 | 0.18 | 0.23 | 0.30 | ||||||||||
| PBT | 4.62 | 4.87 | 4.84 | 8.20 | 31.26 | 40.89 | 59.03 | 77.47 | 79.33 | 70.69 | ||||||||||
| Taxes & Other Items | 0.00 | 0.50 | 0.97 | 1.79 | 7.59 | 10.71 | 15.41 | 19.50 | 20.18 | 18.00 | ||||||||||
| Net Income | 4.62 | 4.37 | 3.87 | 6.41 | 23.67 | 30.18 | 43.62 | 57.97 | 59.15 | 52.69 | ||||||||||
| EPS | 0.42 | 0.40 | 0.36 | 0.59 | 2.17 | 2.77 | 4.00 | 5.32 | 5.43 | 4.84 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.00 | 1.47 | 0.72 | 3.33 | 0.67 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.37 | 0.14 | 0.61 | 0.14 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Gujarat Themis Biosyn Ltd | 60.06 | 17.64 | 1.02% |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare GUJTHEM with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 2.24%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 3 Mutual Funds holding Gujarat Themis Biosyn Ltd
| Funds (Top 3) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
quant Manufacturing Fund - Growth Option - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9208% | Percentage of the fund’s portfolio invested in the stock 3.25% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/38 (0) |
Quant Value Fund - Direct Plan Growth Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.2359% | Percentage of the fund’s portfolio invested in the stock 0.43% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 29/42 (-8) |
Bandhan BSE Healthcare Index Fund Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.08% | Change in the portfolio weight of the stock over the last 3 months 0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 80/102 (-4) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 15, 2024
Dividend/Share
₹0.25
Ex DateEx Date
Jul 15, 2024
Cash Dividend
Ex DateEx DateFeb 22, 2024
Dividend/Share
₹0.75
Ex DateEx Date
Feb 22, 2024
Cash Dividend
Ex DateEx DateSep 1, 2023
Dividend/Share
₹1.00
Ex DateEx Date
Sep 1, 2023
Cash Dividend
Ex DateEx DateDec 1, 2022
Dividend/Share
₹4.40
Ex DateEx Date
Dec 1, 2022
Cash Dividend
Ex DateEx DateAug 29, 2022
Dividend/Share
₹4.00
Ex DateEx Date
Aug 29, 2022
The Board of Directors of Gujarat Themis Biosyn (GTBL) and Themis Medicare (TML) have approved a Scheme of Amalgamation of Gujarat Themis Biosyn with Themis Medicare. The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL, the stock exchanges, SEBI, NCLT and other regulatory approvals as may be required. This amalgamation will result in consolidation of businesses and integration of the entire product value chain under a single amalgamated entity, leading to significant synergies. Under the scheme, TML will issue and allot 118 equity shares of the face value of Re. 1 each, credited as fully paid-up, for every 100 equity shares of the face value of Re. 1 each fully paid-up, held by shareholders in GTBL.Powered by Capital Market - Live
Net profit of Gujarat Themis Biosyn declined 15.71% to Rs 10.57 crore in the quarter ended September 2024 as against Rs 12.54 crore during the previous quarter ended September 2023. Sales declined 12.19% to Rs 34.72 crore in the quarter ended September 2024 as against Rs 39.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales34.7239.54 -12 OPM %44.3542.26 - PBDT15.6417.76 -12 PBT14.2016.88 -16 NP10.5712.54 -16 Powered by Capital Market - Live
Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live
This decline was primarily driven by a 21.7% YoY drop in net sales to Rs 38.83 crore. Total operating expenses also decreased by 22.2% to Rs 20.28 crore in the June'24 quarter. Consequently, PBIDT decreased by 22.4% YoY to Rs 19.07 crore in Q1 FY25, with a margin of 49.11% (down from 49.57% in Q1 FY24). Further, the company's depreciation charges increased by 53.3% YoY to Rs 1.15 crore during the period under review. As a result, profit before tax fell by 25% to Rs 17.86 crore in Q1 FY25 compared to Rs 23.81 crore in the corresponding quarter of the previous year. Gujarat Themis Biosyn is engaged in the manufacturing of APIs, namely, Rifamycin S and Rifamycin O. The scrip had declined 3.91% to end at Rs 483.75 on the BSE on Friday. In the last one year, the stock of Gujarat Themis Biosyn has surged 207.26% while the benchmark Sensex had risen 21.92% in the same period. Powered by Capital Market - Live
The Board of Gujarat Themis Biosyn has approved the appointment of K. G. Ananthakrishnan (DIN: 00019325) as an Additional Independent Director of the Company w.e.f. 26 July 2024. Powered by Capital Market - Live
Gujarat Themis Biosyn has fixed 09 August 2024 as record date for issuance of bonus shares. Powered by Capital Market - Live
Net profit of Gujarat Themis Biosyn declined 25.28% to Rs 13.24 crore in the quarter ended June 2024 as against Rs 17.72 crore during the previous quarter ended June 2023. Sales declined 21.70% to Rs 38.83 crore in the quarter ended June 2024 as against Rs 49.59 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales38.8349.59 -22 OPM %47.8047.43 - PBDT19.0124.56 -23 PBT17.8623.81 -25 NP13.2417.72 -25 Powered by Capital Market - Live
Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 32.13%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.02% to 0.05%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 55.96%, vs industry avg of 15.27%